// App-Quantinova.ai

TPS149 : Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

Researchers

Presenter

  • Josep Tabernero

Principal Investigators

  • Eric Van Cutsem

  • Jana Prausov

  • Nicolas Isambert

  • Cindy Neuzillet

  • Salvatore Siena

  • Filippo Pietrantonio

  • Stephen Falk

  • Zev A. Wainberg

  • Kanwal Pratap Singh Raghav

  • Nicole Campbell

  • Eva Liu

  • Regina Esser

  • Shaista Salim

  • Frank Beier

  • Svenja Adrian

  • Elena Elez

  • Tanios S. Bekaii-Saab

Medical Centers

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Dept. of Urology, Faculty Hospital, Praque, Czech Republic

  • CHU Poitiers, Poitiers, France

  • Curie Institute, Saint Cloud, France

  • Azienda Socio Sanitaria Territoriale Niguarda, Milan, Italy

  • Istituto Nazionale Tumori, Milano, Italy

  • Bristol Oncology, Bristol, United Kingdom

  • UCLA Medical Ctr, Santa Monica, Santa Monica, CA

  • 1.MD Anderson Cancer Center, Houston, TX

  • EMD Serono, A Division of EMD Inc., A Subsidiary of Merck KGaA, Darmstadt, Germany

  • Merck KGaA, Darmstadt, Germany

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

Locations

  • Spain

  • Belgium

  • Czech Republic

  • France

  • Italy

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Erbitux

  • Tepotinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • NCT01982955

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved